Trial Profile
A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Oct 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRONOUNCE
- Sponsors Eli Lilly and Company
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 18 Aug 2020 Planned End Date changed from 15 Aug 2020 to 15 Nov 2020.
- 02 Mar 2020 Planned End Date changed from 15 Feb 2020 to 15 Aug 2020.